OncologyEducation presents MedOncNow
In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib.
21 episodes
Comments
0Be the first to comment
Sign up now and become a member of the OncologyEducation presents MedOncNow community!